Products & Reviews

MammaPrint Provides Individualized Metastasis Risk Assessment for Your Breast Cancer Patients MammaPrint is the first FDA-cleared IVDMIA breast cancer recurrence assay. The unique 70-gene signature of MammaPrint provides you with the unprecedented ability to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery, independent of Estrogen Receptor status and any prior treatment. Unl…

The BluePrint Molecular Subtyping Profile combined with the patient's MammaPrint test result, provides a greater level of clinical information to assist in therapeutic decision-making. BluePrint is an 80-gene expression signature which classifies breast cancer into Basal-type, Luminal-type and ERBB2-type cancers. An increasing body of evidence in the medical community suggests that breast cancer patients within these molecular…